Roche has agreed to out-license certain rights to its invesitgational atropic dermatitis drug lebrikizumab to Demira in a deal that could be worth more than $1.4 billion.

Dermira will obtain exclusive, worldwide rights to develop and commercialize lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications – except for interstitial lung diseases, such as idiopathic pulmonary fibrosis, the rights for which will remain with Roche.

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *